The transformative potential of microfluidics in the development of mRNA vaccines is explored in this review, highlighting its pivotal role in enhancing easy-to-use functionality, efficacy, and production efficiency. Moreover, we examine the innovative applications of microfluidics in biomedical research, including its contribution to the rapid and cost-effective synthesis of lipid nanoparticles for mRNA delivery and delve into the advantages of mRNA vaccines, such as targeted delivery and controlled expression. Furthermore, it outlines the future prospects of microfluidic devices, their cutting-edge examples in both research and industry, and the potential to revolutionize vaccine formulation and production. The integration of microfluidics with mRNA vaccine development represents a significant advancement in public health and disease prevention strategies.
REFERENCES
1.
C.
Lopes
, J.
Cristóvão
, V.
Silvério
, P. R.
Lino
, and P.
Fonte
, “Microfluidic production of mRNA-loaded lipid nanoparticles for vaccine applications
,” Expert Opin. Drug Delivery
19
(10
), 1381
–1395
(2022
). 2.
J.
Viola
, D.
Rafael
, E.
Wagner
, R.
Besch
, and M.
Ogris
, “Gene therapy for advanced melanoma: Selective targeting and therapeutic nucleic acids
,” J. Drug Delivery
2013
, 897348
(2013
). 3.
F.
Jacob
and J.
Monod
, “Genetic regulatory mechanisms in the synthesis of proteins
,” J. Mol. Biol.
3
(3
), 318
–356
(1961
). 4.
S.
Brenner
, F.
Jacob
, and M.
Meselson
, “An unstable intermediate carrying information from genes to ribosomes for protein synthesis
,” Nature
190
, 576
–581
(1961). 5.
P. A.
Sharp
, “Split genes and RNA splicing (nobel lecture)
,” Angew. Chem., Int. Ed. Engl.
33
(12
), 1229
–1240
(1994
). 6.
J. A.
Wolff
, R. W.
Malone
, P.
Williams
, W.
Chong
, G.
Acsadi
, A.
Jani
, and P. L.
Felgner
, “Direct gene transfer into mouse muscle in vivo
,” Science
247
(4949
), 1465
–1468
(1990
). 7.
K.
Karikó
, M.
Buckstein
, H.
Ni
, and D.
Weissman
, “Suppression of RNA recognition by toll-like receptors: The impact of nucleoside modification and the evolutionary origin of RNA
,” Immunity
23
(2
), 165
–175
(2005
). 8.
S.
Rausch
, C.
Schwentner
, A.
Stenzl
, and J.
Bedke
, “mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer
,” Hum. Vaccines Immunother.
10
(11
), 3146
–3152
(2014
). 9.
M.
Gao
, Q.
Zhang
, X.-H.
Feng
, and J.
Liu
, “Synthetic modified messenger RNA for therapeutic applications
,” Acta Biomater.
131
, 1
–15
(2021
). 10.
M. A.
Liu
, “Immunologic basis of vaccine vectors
,” Immunity
33
(4
), 504
–515
(2010
). 11.
M.
Hilleman
, “Recombinant vector vaccines in vaccinology
,” Dev. Biol. Stand.
82
, 3
–20
(1994
).12.
T.
Schlake
, A.
Thess
, M.
Fotin-Mleczek
, and K.-J.
Kallen
, “Developing mRNA-vaccine technologies
,” RNA Biol.
9
(11
), 1319
–1330
(2012
). 13.
M.
Liu
, “Immunologic basis of vaccine vectors
,” Immunity
33
, 504
–515
(2010
). 14.
F. P.
Polack
, S. J.
Thomas
, N.
Kitchin
, J.
Absalon
, A.
Gurtman
, S.
Lockhart
, J. L.
Pérez
, G. P.
Marc
, E. D.
Moreira
, C.
Zerbini
, R.
Bailey
, K. A.
Swanson
, S.
Roychoudhury
, K.
Koury
, P.
Li
, W. V.
Kalina
, D.
Cooper
, R. W.
Frenck
, L. L.
Hammitt
, Ö.
Türeci
, H.
Nell
, A.
Schaefer
, S.
Ünal
, D. B.
Tresnan
, S.
Mather
, P. R.
Dormitzer
, U.
Şahin
, K. U.
Jansen
, and W. C.
Gruber
, “Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine
,” N. Engl. J. Med.
383
(27
), 2603
–2615
(2020
). 15.
H. M.
El Sahly
, L. R.
Baden
, B.
Essink
, S.
Doblecki-Lewis
, J. M.
Martin
, E. J.
Anderson
, T. B.
Campbell
, J.
Clark
, L. A.
Jackson
, C. J.
Fichtenbaum
, M.
Zervos
, B.
Rankin
, F.
Eder
, G.
Feldman
, C.
Kennelly
, L.
Han-Conrad
, M.
Levin
, K. M.
Neuzil
, L.
Corey
, P.
Gilbert
, H.
Janes
, D.
Follmann
, M.
Marovich
, L.
Polakowski
, J. R.
Mascola
, J. E.
Ledgerwood
, B. S.
Graham
, A.
August
, H.
Clouting
, W.
Deng
, S.
Han
, B.
Leav
, D.
Manzo
, R.
Pajon
, F.
Schödel
, J. E.
Tomassini
, H.
Zhou
, and J.
Miller
, “Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase
,” N. Engl. J. Med.
385
(19
), 1774
–1785
(2021
). 16.
S.
Pascolo
, “Vaccination with messenger RNA
,” in DNA Vaccines. Methods in Molecular Medicine™
, edited by W. M Saltzman, H. Shen, and J. L. Brandsma (Humana Press, 2006), Vol. 127
.17.
J.
Probst
, B.
Weide
, B.
Scheel
, B. J.
Pichler
, I.
Hoerr
, H.-G.
Rammensee
, and S.
Pascolo
, “Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent
,” Gene Ther.
14
, 1175
–1180
(2007
). 18.
C.
Iavarone
, D. T.
O’hagan
, D.
Yu
, N. F.
Delahaye
, and J. B.
Ulmer
, “Mechanism of action of mRNA-based vaccines
,” Expert Rev. Vaccines
16
(9
), 871
–881
(2017
). 19.
M.
Maeki
, S.
Uno
, A.
Niwa
, Y.
Okada
, and M.
Tokeshi
, “Microfluidic technologies and devices for lipid nanoparticle-based RNA delivery
,” J. Controlled Release
344
, 80
–96
(2022
). 20.
S. S.
Rosa
, D. M. F.
Prazeres
, A. M.
Azevedo
, and M. P. C.
Marques
, “mRNA vaccines manufacturing: Challenges and bottlenecks
,” Vaccine
39
(16
), 2190
–2200
(2021
). 21.
H.
Andersson
and A.
van den Berg
, “Microfluidic devices for cellomics: A review
,” Sens. Actuators, B
92
(3
), 315
–325
(2003
). 22.
G. S.
Fiorini
and D. T.
Chiu
, “Disposable microfluidic devices: Fabrication, function, and application
,” BioTechniques
38
(3
), 429
–446
(2005
). 23.
A.-G.
Niculescu
, C.
Chircov
, A. C.
Bîrcă
, and A. M.
Grumezescu
, “Fabrication and applications of microfluidic devices: A review
,” Int. J. Mol. Sci.
22
(4
), 2011
(2021
). 24.
B. K.
Gale
, A. R.
Jafek
, C. J.
Lambert
, B. L.
Goenner
, H.
Moghimifam
, U. C.
Nze
, and S. K.
Kamarapu
, “A review of current methods in microfluidic device fabrication and future commercialization prospects
,” Inventions
3
(3
), 60
(2018
). 25.
M.
Dou
, D. C.
Dominguez
, X. J.
Li
, J.
Sanchez
, and G. Scott, “A versatile PDMS/paper hybrid microfluidic platform for sensitive infectious disease diagnosis
,” Anal. Chem.
86
(15), 7978–7986 (2014
).26.
Y.
Yang
, E.
Noviana
, M. P.
Nguyen
, B. J.
Geiss
, D. S.
Dandy
, and C. S.
Henry
, “Based microfluidic devices: Emerging themes and applications
,” Anal. Chem.
89
(1
), 71
–91
(2017
). 27.
G. M.
Whitesides
, “The origins and the future of microfluidics
,” Nature
442
, 368
–373
(2006
). 28.
I. U.
Khan
, C. A.
Serra
, N.
Anton
, and T. F.
Vandamme
, “Production of nanoparticle drug delivery systems with microfluidics tools
,” Expert Opin. Drug Delivery
12
(4
), 547
–562
(2015
). 29.
N.
Zhang
, H.
Tan
, and E. S.
Yeung
, “Analytical chemistry
,” Anal. Chem.
71
(6
), 1138
–1145
(1999
). 30.
R.
Barry
and D.
Ivanov
, “Microfluidics in biotechnology
,” J. Nanobiotechnol.
2
, 2
(2004
). 31.
J.
Clark
, T.
Shevchuk
, P. M.
Swiderski
, R.
Dabur
, L. E.
Crocitto
, Y. I.
Buryanov
, and S. S.
Smith
, “Mobility-shift analysis with microfluidics chips
,” BioTechniques
35
(3
), 548
–554
(2003
). 32.
D.
Figeys
, S. P.
Gygi
, G.
McKinnon
, and R.
Aebersold
, “An integrated microfluidics-tandem mass spectrometry system for automated protein analysis
,” Anal. Chem.
70
(18
), 3728
–3734
(1998
). 33.
D.
Figeys
and R.
Aebersold
, “High sensitivity analysis of proteins and peptides by capillary electrophoresis-tandem mass spectrometry: Recent developments in technology and applications
,” Electrophoresis
19
(6
), 885
–892
(1998
). 34.
N.
Lion
, J.-O.
Gellon
, H.
Jensen
, and H. H.
Girault
, “On-chip protein sample desalting and preparation for direct coupling with electrospray ionization mass spectrometry
,” J. Chromatogr., A
1003
(1–2
), 11
–19
(2003
). 35.
M. I.
Hajam
and M. M.
Khan
, “Microfluidics: A concise review of the history, principles, design, applications, and future outlook
,” Biomater. Sci.
12
, 218–251 (2024
).36.
L. L.
Cavalli-Sforza
, “The human genome diversity project: Past, present and future
,” Nat. Rev. Genet.
6
, 333
–340
(2005
). 37.
F. S.
Collins
, M.
Morgan
, and A.
Patrinos
, “The human genome project: Lessons from large-scale biology
,” Science
300
(5617
), 286
–290
(2003
). 38.
A.
Gevaerd
, E. Y.
Watanabe
, C.
Belli
, L. H.
Marcolino-Junior
, and M. F.
Bergamini
, “A complete lab-made point of care device for non-immunological electrochemical determination of cortisol levels in salivary samples
,” Sens. Actuators, B
332
, 129532
(2021
). 39.
V. M.
Smith
, H.
Nguyen
, J. W.
Rumsey
, C. J.
Long
, M. L.
Shuler
, and J. J.
Hickman
, “A functional human-on-a-chip autoimmune disease model of myasthenia gravis for development of therapeutics
,” Front. Cell Dev. Biol.
9
, 745897
(2021
). 40.
D. S.
Younger
, A. P.
Younger
, and S.
Guttmacher
, “Childhood vaccination: Implications for global and domestic public health
,” Neurol. Clin.
34
, 1035
–1047
(2016
). 41.
World Health Organization
, see http://www.who.int/mediacentre/factsheets/fs378/en for “Immunization Coverage” (2017
).42.
S. A.
Plotkin
, “Vaccines: The fourth century
,” Clin. Vaccine Immunol.
16
, 1709
–1719
(2009
). 43.
U.
Sahin
, K.
Karikó
, and Ö.
Türeci
, “mRNA-based therapeutics — Developing a new class of drugs
,” Nat. Rev. Drug Discovery
13
, 759
–780
(2014
). 44.
C. M. C.
Rodrigues
, M. V.
Pinto
, M.
Sadarangani
, and S. A.
Plotkin
, “Whither vaccines?
,” J. Infect.
74
, S2
–S9
(2017
). 45.
N.
Pardi
, S.
Tuyishime
, H.
Muramatsu
, K.
Kariko
, B. L.
Mui
, Y. K.
Tam
, T. D.
Madden
, M. J.
Hope
, and D.
Weissman
, “Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes
,” J. Controlled Release
217
, 345
–351
(2015
). 46.
S.
Tandrup Schmidt
, C.
Foged
, K.
Smith Korsholm
, T.
Rades
, and D.
Christensen
, “Liposome-based adjuvants for subunit vaccines: Formulation strategies for subunit antigens and immunostimulators
,” Pharmaceutics
8
(1
), 7
(2016
). 47.
B.
Petsch
, M.
Schnee
, A. B.
Vogel
, E.
Lange
, B.
Hoffmann
, D.
Voss
, T.
Schlake
, A.
Thess
, K.-J.
Kallen
, L.
Stitz
, and T.
Kramps
, “Protective efficacy of in vitro synthesized, specific mRNA vaccines against influenza a virus infection
,” Nat. Biotechnol.
30
, 1210
–1216
(2012
). 48.
K.
Karikó
, H.
Muramatsu
, F. A.
Welsh
, J.
Ludwig
, H.
Kato
, S.
Akira
, and D.
Weissman
, “Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability
,” Mol. Ther.
16
(11
), 1833
–1840
(2008
). 49.
V.
Gote
, P. K.
Bolla
, N.
Kommineni
, A.
Butreddy
, P. K.
Nukala
, S. S.
Palakurthi
, and W.
Khan
, “A comprehensive review of mRNA vaccines
,” Int. J. Mol. Sci.
24
(3
), 2700
(2023
). 50.
J.
Kim
, Y.
Eygeris
, M.
Gupta
, and G.
Sahay
, “Self-assembled mRNA vaccines
,” Adv. Drug Delivery Rev.
170
, 83
–112
(2021
). 51.
R.
Firdessa-Fite
and R. J.
Creusot
, “Nanoparticles versus dendritic cells as vehicles to deliver mRNA encoding multiple epitopes for immunotherapy
,” Mol. Ther. Methods Clin. Dev.
16
, 50
–62
(2020
). 52.
N.
Pardi
, M. J.
Hogan
, F. W.
Porter
, and D.
Weissman
, “mRNA vaccines—A new era in vaccinology
,” Nat. Rev. Drug Discovery
17
(4
), 261
–279
(2018
). 53.
S. H.
Kiaie
, N.
Majidi Zolbanin
, A.
Ahmadi
, R.
Bagherifar
, H.
Valizadeh
, F.
Kashanchi
, and R.
Jafari
, “Recent advances in mRNA-LNP therapeutics: Immunological and pharmacological aspects
,” J. Nanobiotechnol.
20
(1
), 276
(2022
). 54.
O. F.
Khan
, J.
Couture-Senécal
, Y. M. A.
Lau
, A.-M.
Oproescu
, J.
Pang
, G.
Tilstra
, and B. A.
Walz
, “mRNA vaccines: Immunology and present and future potential
,” in The COVID-19 Pandemic: Science, Technology, and the Future of Healthcare Delivery
(Springer
, 2024
), pp. 79
–112
.55.
Y.
Zhu
, J.
Ma
, R.
Shen
, J.
Lin
, S.
Li
, X.
Lu
, J. L.
Stelzel
, J.
Kong
, L.
Cheng
, I.
Vuong
, Z.-C.
Yao
, C.
Wei
, N. M.
Korinetz
, W. H.
Toh
, J.
Choy
, R. A.
Reynolds
, M. J.
Shears
, W. J.
Cho
, N. K.
Livingston
, G. P.
Howard
, Y.
Hu
, S. Y.
Tzeng
, D. J.
Zack
, J. J.
Green
, L.
Zheng
, J. C.
Doloff
, J. P.
Schneck
, S. K.
Reddy
, S. C.
Murphy
, and H.-Q.
Mao
, “Screening for lipid nanoparticles that modulate the immune activity of helper T cells towards enhanced antitumour activity
,” Nat. Biomed. Eng.
8
(5
), 544
–560
(2024
). 56.
Y.
Wu
, H.
Zhang
, L.
Meng
, F.
Li
, and C.
Yu
, “Comparison of immune responses elicited by SARS-CoV-2 mRNA and recombinant protein vaccine candidates
,” Front. Immunol.
13
, 906457
(2022
). 57.
D. D.
Kang
, H.
Li
, and Y.
Dong
, “Advancements of in vitro transcribed mRNA (IVT mRNA) to enable translation into the clinics
,” Adv. Drug Delivery Rev.
199
, 114961
(2023
). 58.
M.
Tusup
, L. E.
French
, M.
De Matos
, D.
Gatfield
, T.
Kundig
, and S.
Pascolo
, “Design of in vitro transcribed mRNA vectors for research and therapy
,” Chimia
73
, 391
–394
(2019
). 59.
R.
Lenk
, W.
Kleindienst
, G. T.
Szabó
, M.
Baiersdörfer
, G.
Boros
, J. M.
Keller
, A. J.
Mahiny
, and I.
Vlatkovic
, “Understanding the impact of in vitro transcription byproducts and contaminants
,” Front. Mol. Biosci.
11
, 1426129
(2024
). 60.
H.
Kwon
, M.
Kim
, Y.
Seo
, Y. S.
Moon
, H. J.
Lee
, K.
Lee
, and H.
Lee
, “Emergence of synthetic mRNA: In vitro synthesis of mRNA and its applications in regenerative medicine
,” Biomaterials
156
, 172
–193
(2018
). 61.
K.
Karikó
, H.
Muramatsu
, J.
Ludwig
, and D.
Weissman
, “Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA
,” Nucleic Acids Res.
39
, e142
(2011
). 62.
S.
Kwon
, M.
Kwon
, S.
Im
, K.
Lee
, and H.
Lee
, “mRNA vaccines: The most recent clinical applications of synthetic mRNA
,” Arch. Pharmacal. Res.
45
(4
), 245
–262
(2022
). 63.
Y.
Liang
, L.
Huang
, and T.
Liu
, “Development and delivery systems of mRNA vaccines
,” Front. Bioeng. Biotechnol.
9
, 718753
(2021
). 64.
A.
Wadhwa
, A.
Aljabbari
, A.
Lokras
, C.
Foged
, and A.
Thakur
, “Opportunities and challenges in the delivery of mRNA-based vaccines
,” Pharmaceutics
12
(2
), 102
(2020
). 65.
R.
Maurer
, R.
Stone
, and J.
Gorski
, “Cell-free synthesis of a large translation product of prolactin messenger RNA
,” J. Biol. Chem.
251
(9
), 2801
–2807
(1976
). 66.
A.
Brookwell
, J. P.
Oza
, and F.
Caschera
, “Biotechnology applications of cell-free expression systems
,” Life
11
(12
), 1367
(2021
). 67.
V.
Sharma
, A.
Mottafegh
, J.-U.
Joo
, J.-H.
Kang
, L.
Wang
, and D.-P.
Kim
, “Toward microfluidic continuous-flow and intelligent downstream processing of biopharmaceuticals
,” Lab Chip
24
(11
), 2861
–2882
(2024
). 68.
C. B.
Roces
, G.
Lou
, N.
Jain
, S.
Abraham
, A.
Thomas
, G. W.
Halbert
, and Y.
Perrie
, “Manufacturing considerations for the development of lipid nanoparticles using microfluidics
,” Pharmaceutics
12
(11
), 1095
(2020
). 69.
I.
MacLachlan
, “Liposomal formulations for nucleic acid delivery
,” Antisense Drug Technol.
2
, 237
–270
(2007
). 70.
G.
Prakash
, A.
Shokr
, N.
Willemen
, S. M.
Bashir
, S. R.
Shin
, and S.
Hassan
, “Microfluidic fabrication of lipid nanoparticles for the delivery of nucleic acids
,” Adv. Drug Delivery Rev.
184
, 114197
(2022
). 71.
S. M.
Saravanakumar
and P.-V.
Cicek
, “Microfluidic mixing: A physics-oriented review
,” Micromachines
14
(10), 1827 (2023
).72.
K.
Karimi
, A.
Fardoost
, N.
Mhatre
, J.
Rajan
, D.
Boisvert
, and M. A.
Javanmard
, “Thorough review of emerging technologies in micro- and nanochannel fabrication: Limitations, applications, and comparison
,” Micromachines
15
(10
), 1274
(2024
).73.
S. J.
Shepherd
, D.
Issadore
, and M. J.
Mitchell
, “Microfluidic formulation of nanoparticles for biomedical applications
,” Biomaterials
274
, 120826
(2021
). 74.
F.
Tian
, L.
Cai
, C.
Liu
, and J.
Sun
, “Microfluidic technologies for nanoparticle formation
,” Lab Chip
22
(3
), 512
–529
(2022
). 75.
S.
Naher
, D.
Orpen
, D.
Brabazon
, and M. M.
Morshed
, “An overview of microfluidic mixing application
,” in Advanced Materials
(Research. Trans. Tech. Publications, Ltd., 2009
), Vols. 83–86
, pp. 931–939.76.
M.
Maeki
, N.
Kimura
, Y.
Sato
, H.
Harashima
, and M.
Tokeshi
, “Advances in microfluidics for lipid nanoparticles and extracellular vesicles and applications in drug delivery systems
,” Adv. Drug Delivery Rev.
128
, 84
–100
(2018
). 77.
A.
Dietzel
, “A brief introduction to microfluidics
,” in Microsystems for Pharmatechnology
, edited by A. Dietzel (Springer, Cham., 2016
), pp. 1
–25
.78.
S.
Zhang
, Y.
Fan
, C.
Xue
, Y.
Yang
, X.
Li
, X.
Chen
, and Y.
Deng
, “Mixing dynamics and synthesis performance of staggered herringbone micromixer for limit size lipid nanoparticles
,” J. Beijing Inst. Technol.
31
(3
), 293
–301
(2022
).79.
Y.
Zhao
, G.
Chen
, and Q.
Yuan
, “Liquid–liquid two-phase mass transfer in the T-junction microchannels
,” AIChE J.
53
(12
), 3042
–3053
(2007
). 80.
G.-B.
Lee
, C.-I.
Hung
, B.-J.
Ke
, G.-R.
Huang
, B.-H.
Hwei
, and H.-F.
Lai
, “Hydrodynamic focusing for a micromachined flow cytometer
,” J. Fluids Eng.
123
(3
), 672
–679
(2001
). 81.
I. V.
Zhigaltsev
, N.
Belliveau
, I.
Hafez
, A. K. K.
Leung
, J.
Huft
, C.
Hansen
, and P. R.
Cullis
, “Bottom-up design and synthesis of limit size lipid nanoparticle systems with aqueous and triglyceride cores using millisecond microfluidic mixing
,” Langmuir
28
(7
), 3633
–3640
(2012
). 82.
M.
Maeki
, T.
Saito
, Y.
Sato
, T.
Yasui
, N.
Kaji
, A.
Ishida
, H.
Tani
, Y.
Baba
, H.
Harashima
, and M.
Tokeshi
, “A strategy for synthesis of lipid nanoparticles using microfluidic devices with a mixer structure
,” RSC Adv.
5
(57
), 46181
–46185
(2015
). 83.
T.
Lorenz
, S.
Bojko
, H.
Bunjes
, and A.
Dietzel
, “An inert 3D emulsification device for individual precipitation and concentration of amorphous drug nanoparticles
,” Lab Chip
18
(4
), 627
–638
(2018
). 84.
K.
Conlisk
and G. M.
O’Connor
, “Analysis of passive microfluidic mixers incorporating 2D and 3D baffle geometries fabricated using an excimer laser
,” Microfluidics Nanofluidics
12
, 941
–951
(2012
). 85.
H.
Jang
, M. R.
Haq
, J.
Ju
, Y.
Kim
, S.-m.
Kim
, and J.
Lim
, “Fabrication of all glass bifurcation microfluidic chip for blood plasma separation
,” Micromachines
8
(3
), 67
(2017
). 86.
M.
Maeki
, Y.
Fujishima
, Y.
Sato
, T.
Yasui
, N.
Kaji
, A.
Ishida
, H.
Tani
, Y.
Baba
, H.
Harashima
, and M.
Tokeshi
, “Understanding the formation mechanism of lipid nanoparticles in microfluidic devices with chaotic micromixers
,” PLoS One
12
(11
), e0187962
(2017
). 87.
D.
Chen
, K. T.
Love
, Y.
Chen
, A. A.
Eltoukhy
, C.
Kastrup
, G.
Sahay
, A.
Jeon
, Y.
Dong
, K. A.
Whitehead
, and D. G.
Anderson
, “Rapid discovery of potent siRNA-containing lipid nanoparticles enabled by controlled microfluidic formulation
,” J. Am. Chem. Soc.
134
(16
), 6948
–6951
(2012
). 88.
M. D.
Buschmann
, M. J.
Carrasco
, S.
Alishetty
, M.
Paige
, M. G.
Alameh
, and D.
Weissman
, “Nanomaterial delivery systems for mRNA vaccines
,” Vaccines
9
(1
), 65
(2021
). 89.
J. A.
Kulkarni
, M. M.
Darjuan
, J. E.
Mercer
, S.
Chen
, R.
Van Der Meel
, J. L.
Thewalt
, Y. Y. C.
Tam
, and P. R.
Cullis
, “On the formation and morphology of lipid nanoparticles containing ionizable cationic lipids and siRNA
,” ACS Nano
12
(5
), 4787
–4795
(2018
). 90.
W.-Z. S.
Lin
, W. K. V.
Bostic
, and N.
Malmstadt
, “3D-printed microfluidic device for high-throughput production of lipid nanoparticles incorporating SARS-CoV-2 spike protein mRNA
,” Lab Chip
24
(2
), 162
–170
(2024
). 91.
S. J.
Shepherd
, C. C.
Warzecha
, S.
Yadavali
, R.
El-Mayta
, M.-G.
Alameh
, L.
Wang
, D.
Weissman
, J. M.
Wilson
, D.
Issadore
, and M. J.
Mitchell
, “Scalable mRNA and siRNA lipid nanoparticle production using a parallelized microfluidic device
,” Nano Lett.
21
(13
), 5671
–5680
(2021
). 92.
S. J.
Shepherd
, X.
Han
, A. J.
Mukalel
, R.
El-Mayta
, A. S.
Thatte
, J.
Wu
, M. S.
Padilla
, M.-G.
Alameh
, N.
Srikumar
, D.
Lee
, D.
Weissman
, D.
Issadore
, and M. J.
Mitchell
, “Throughput-scalable manufacturing of SARS-CoV-2 mRNA lipid nanoparticle vaccines
,” Proc. Natl. Acad. Sci. U.S.A.
120
(33
), e2303567120
(2023
). 93.
W.-Z. S.
Lin
, W. K. V.
Bostic
, and N.
Malmstadt
, “3D-printed microfluidic device for high-throughput production of lipid nanoparticles incorporating SARS-CoV-2 spike protein mRNA
,” Lab Chip
24
, 162
–170
(2024
). 94.
R.
Palanki
, E. L.
Han
, A. M.
Murray
, R.
Maganti
, S.
Tang
, K. L.
Swingle
, D.
Kim
, H.
Yamagata
, H. C.
Safford
, K.
Mrksich
, W. H.
Peranteau
, and M. J.
Mitchell
, “Optimized microfluidic formulation and organic excipients for improved lipid nanoparticle mediated genome editing
,” Lab Chip
24
, 3790
–3801
(2024
). 95.
MilliporeSigma
, see https://www.sigmaaldrich.com/US/en/technical-documents/technical-article/materials-science-and-engineering/drug-delivery/nanofabtx-a-ready-to-use-microfluidic-platform-for-mRNA-vaccine for “Nanofabtx™: A Ready-to-Use Microfluidic Platform for mRNA Vaccine Formulation” (2021
) (last accessed May 6, 2024).96.
Fluigent
, see https://www.fluigent.com/resources-support/expertise/expertise-reviews/microfluidics-for-vaccines-research-and-development/ for “Advanced Microfluidic Control Systems for Precision Fluid Handling” (2021
) (last accessed May 6, 2024).97.
RedShiftBio—Apollo
, see https://www.redshiftbio.com/biomolecules/nucleic-acid for “Aurora TX: Microfluidic Modulation Spectroscopy for RNA and Protein Analysis” (2021
) (last accessed May 6, 2024).98.
Cytiva—NxGen Technology
, see https://www.precisionnanosystems.com/resources-and-community/knowledge-center/articles/detail/nxgen-technology-for-scaling-nanoparticle-production for “Nxgen™ Microfluidic Devices for Scalable Nanoparticle Production” (2021
) (last accessed May 6, 2024).99.
Microfluidics InteRNAtional Corporation
, see https://www.microfluidics-mpt.com/microfluidizers for “Microfluidizer® Technology for High Shear Fluid Processing” (2021
) (last accessed May 6, 2024).100.
Precigenome LLC
, see https://www.precigenome.com/lipid-nanoparticles-lnp/lipid-nanoparticle-synthesis-system-application for “Lipid Nanoparticle Synthesis System Application” (2024
) (last accessed May 6, 2024).© 2024 Author(s). Published under an exclusive license by AIP Publishing.
2024
Author(s)
You do not currently have access to this content.
